Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer Aysegul ErmanArlene NugentPeter C. Coyte Review 26 April 2014 Pages: 267 - 279
Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes Keely M. McNamaraTomomi YodaHironobu Sasano Preclinical study 09 April 2014 Pages: 281 - 293
Prognostic relevance of glycosylation-associated genes in breast cancer Karin Milde-LangoschThomas KarnVolkmar Müller Preclinical study 16 April 2014 Pages: 295 - 305
RANK expression as a prognostic and predictive marker in breast cancer Berit Maria PfitznerDaniel BranstetterGunter von Minckwitz Preclinical study 16 April 2014 Pages: 307 - 315
Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer Dena A. JerjeesM. AlabdullahEmad A. Rakha Preclinical study 18 April 2014 Pages: 317 - 330
Surgical excision of radial scars diagnosed by core biopsy may help predict future risk of breast cancer Cynthia L. MillerJane A. WestMichelle C. Specht Preclinical Study 19 April 2014 Pages: 331 - 338
Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study Mohammed A. AleskandaranyOla H. NegmEmad A. Rakha Preclinical study 26 April 2014 Pages: 339 - 348
The endoplasmic reticulum stress markers GRP78 and CHOP predict disease-free survival and responsiveness to chemotherapy in breast cancer Yi-Zi ZhengZhi-Gang CaoZhi-Ming Shao Preclinical study 30 April 2014 Pages: 349 - 358
Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy Mark R. PickardGwyn T. Williams Preclinical Study 01 May 2014 Pages: 359 - 370
Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study Gilbert DondersPatrick NevenStefan Buchholz Clinical trial Open access 10 April 2014 Pages: 371 - 379
A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes Wendy Y. ChenAnita Giobbie-HurderEva S. Schernhammer Clinical Trial 10 April 2014 Pages: 381 - 388
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling Vandana G. AbramsonM. Cooper LloydCarlos L. Arteaga Clinical trial 11 April 2014 Pages: 389 - 399
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression Masashi AndoHideko YamauchiYasuhiro Fujiwara Clinical trial 12 April 2014 Pages: 401 - 409
A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease Robert ColemanAnne-Kirsti AksnesPatrick Flamen Clinical trial Open access 13 April 2014 Pages: 411 - 418
Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22 Simon D. BaxterWendy A. TeftRichard B. Kim Clinical Trial 18 April 2014 Pages: 419 - 428
Re-attendance at biennial screening mammography following a repeated false positive recall Elisabeth G. KlompenhouwerLucien E. M. DuijmMireille J. M. Broeders Clinical Trial 19 April 2014 Pages: 429 - 437
Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy Gaia PocobelliPolly A. NewcombNoel S. Weiss Epidemiology 27 March 2014 Pages: 439 - 447
Erratum to: Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy Gaia PocobelliPolly A. NewcombNoel S. Weiss Erratum 06 May 2014 Pages: 449 - 449
Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance Harald Martin SurowyChristian SutterBarbara Burwinkel Epidemiology 12 April 2014 Pages: 451 - 460
Adolescent dietary fiber, vegetable fat, vegetable protein, and nut intakes and breast cancer risk Ying LiuGraham A. ColditzNancy Kreiger Epidemiology 16 April 2014 Pages: 461 - 470
Birth size in the most recent pregnancy and maternal mortality in premenopausal breast cancer by tumor characteristics Mohammadhossein HajiebrahimiSven CnattingiusShahram Bahmanyar Epidemiology 18 April 2014 Pages: 471 - 480
Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55–74 years of age Christopher I. LiJanet R. DalingKathleen E. Malone Epidemiology 20 April 2014 Pages: 481 - 489
Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy Rachel A. FreedmanInes Vaz-LuisNancy L. Keating Epidemiology 23 April 2014 Pages: 491 - 501
Prognostic factors for survival in metastatic breast cancer by hormone receptor status A. B. G. KwastA. C. VoogdS. Siesling Epidemiology 26 April 2014 Pages: 503 - 511
Folate intake and the risk of breast cancer: a systematic review and meta-analysis Martin TioJuliana AndriciGuy D. Eslick Epidemiology 29 April 2014 Pages: 513 - 524
Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry Annette L. StantonKeith J. PetrieAnn H. Partridge Epidemiology 30 April 2014 Pages: 525 - 534
Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort Agnès FournierSylvie MesrineNathalie Chabbert-Buffet Epidemiology 30 April 2014 Pages: 535 - 543
Associations between anthropometric characteristics, physical activity, and breast cancer risk in a Canadian cohort Chelsea CatsburgVictoria A. KirshThomas E. Rohan Epidemiology 30 April 2014 Pages: 545 - 552
Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations Anna P. SokolenkoNatalia BogdanovaEvgeny N. Imyanitov Brief Report 07 May 2014 Pages: 553 - 562
Letter in response: breast cancer screening of women aged 70–74 years Robert Burton Letter to the Editor 23 April 2014 Pages: 563 - 564
Rebuttal to: Letter to the Editor by Robert Burton, in response to doi:10.1007/s10549-013-2794-5 Carolyn NicksonKate E MasonAnne M. Kavanagh Rebuttal Letter 01 May 2014 Pages: 565 - 566